NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
85.72
+2.57 (+3.09%)
At close: 4:02PM EDT

85.04 -0.72 (-0.84%)
Pre-Market: 7:22AM EDT

Stock chart is not supported by your current browser
Previous Close83.15
Open84.49
Bid85.03 x 800
Ask85.09 x 1800
Day's Range84.32 - 85.81
52 Week Range72.30 - 94.19
Volume2,827,113
Avg. Volume1,825,718
Market Cap198.721B
Beta (3Y Monthly)0.86
PE Ratio (TTM)14.57
EPS (TTM)5.88
Earnings DateN/A
Forward Dividend & Yield2.98 (3.60%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • TheStreet.com18 hours ago

    Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

    is now official after U.S. District Judge Alison Nathan signed the settlement in Manhattan, Tuesday, Oct. 16. As part of the settlement, Musk will have to step down as chairman of the electric vehicle company and will have to personally pay a $20 million fine in addition to a separate $20 million fine levied against Tesla. The court action comes in the wake of a tweet Musk sent on Aug. 7, suggesting that he had secured enough funding to take the company private at $420 a share.

  • Benzinga21 hours ago

    Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization

    Shares of  Tilray Inc. (NASDAQ: TLRY ) surged Monday in anticipation of Canada’s legalization of recreational marijuana. The Analyst Benchmark analyst Mike Hickey initiated coverage of  Tilray with a Buy ...

  • TheStreet.com22 hours ago

    Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark

    The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.

  • Roche Announces Positive Data on Breast Cancer Drug Kadcyla
    Zacks22 hours ago

    Roche Announces Positive Data on Breast Cancer Drug Kadcyla

    Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.

  • Reuters23 hours ago

    Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

    Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.

  • MarketWatchyesterday

    Tilray's stock surges after Benchmark starts coverage with bullish rating, $200 target

    Shares of Tilray Inc. shot up 5.7% in premarket trade Tuesday, after Benchmark analyst Mike Hickey started coverage of the Canada-based medical cannabis and cannabinoid company with a buy rating and $200 price target. Hickey's price target is 21% above Monday's closing price $165.64. Hickey said his bullish view is based on the company's early leadership in the medical cannabis market in Canada, the upcoming full legalization of recreational marijuana in Canada and its strategic alliance with Novartis AG and supply agreements with Canadian pharmacies, international growth opportunities and a "meaningful" capital infusion from its initial public offering in July. "We believe establishing an early first mover advantage is critically important in the emerging cannabis market, particularly when it comes to building national and global scale, leading brands, and developing innovative products and form factors that use cannabis as an active ingredient," Hickey wrote in a note to clients. The stock has rocketed more than 7-fold since closing at $22.39 on its first day listed on the Nasdaq on July 19, while the ETFMG Alternative Harvest ETF has run up 55% and the S&P 500 has lost 1.9% over the same time.

  • Novartis’ Estimates and Recommendations on October 12
    Market Realist2 days ago

    Novartis’ Estimates and Recommendations on October 12

    Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).

  • Novartis in Q3 2018: Analysts Expect Revenue Growth
    Market Realist2 days ago

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

  • Novartis: What to Expect from Q3 Earnings on October 18
    Market Realist2 days ago

    Novartis: What to Expect from Q3 Earnings on October 18

    Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.

  • An Update on Bausch + Lomb/International in October
    Market Realist2 days ago

    An Update on Bausch + Lomb/International in October

    Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth. 

  • AbbVie Permits US Sale of Sandoz's Humira Biosimilar
    GuruFocus.com5 days ago

    AbbVie Permits US Sale of Sandoz's Humira Biosimilar

    The license will take effect on Sept. 30, 2023

  • Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
    Zacks5 days ago

    Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

    AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

  • AbbVie Settles With Novartis to Delay Humira Biosimilar in US
    Zacks5 days ago

    AbbVie Settles With Novartis to Delay Humira Biosimilar in US

    AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

  • Abbvie settles Humira patent disputes with Novartis unit
    Reuters5 days ago

    Abbvie settles Humira patent disputes with Novartis unit

    Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.

  • Reuters5 days ago

    Abbvie settles Humira patent disputes with Novartis unit

    Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.

  • MarketWatch6 days ago

    AbbVie stock ticks higher as Humira patent dispute with Novartis resolved

    AbbVie Inc. shares ticked higher in the extended session Thursday after the drug maker said it had settled patent disputes with Novartis AG unit Sandoz involving a popular arthritis treatment. AbbVie shares rose 2.4% after hours, following a 2.6% decline to close at $90.70 Thursday. Under an agreement, Sandoz will pay AbbVie royalties of an undisclosed amount for a non-exclusive license of patents for AbbVie's drug Humira, the companies said. Sandoz markets a biosimilar product called Hyrimoz. The license for sale in most European countries will be Oct. 16, while the license for U.S. sales will not start until Sept. 30, 2023.

  • Wall Street Analysts See Upside Potential of 3.9% in TEVA
    Market Realist6 days ago

    Wall Street Analysts See Upside Potential of 3.9% in TEVA

    Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.

  • Novartis Presents Data on Multiple Sclerosis Drug Gilenya
    Zacks6 days ago

    Novartis Presents Data on Multiple Sclerosis Drug Gilenya

    Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist6 days ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • A Look at the Performance of Novartis’s Alcon
    Market Realist6 days ago

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.

  • Could Johnson & Johnson Meet Its Q3 2018 Sales Estimates?
    Market Realist7 days ago

    Could Johnson & Johnson Meet Its Q3 2018 Sales Estimates?

    Johnson & Johnson (JNJ) plans to announce its third-quarter earnings on October 16. According to Reuters estimates, the company is expected to register sales of $20.03 billion. This estimate represents YoY (year-over-year) sales growth of ~1.9%.

  • Novartis Presents Positive Data on Sickle Cell Disease Drug
    Zacks7 days ago

    Novartis Presents Positive Data on Sickle Cell Disease Drug

    Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.

  • Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings
    Market Realist7 days ago

    Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings

    What to Expect from Johnson & Johnson's Q3 2018 EarningsAnalysts’ views on Johnson & Johnson

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist7 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • How Novartis’s Sandoz Business Has Been Performing Recently
    Market Realist7 days ago

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz reported nearly flat revenue of ~$2.46 billion in the second quarter driven by a 2% favorable impact of foreign exchange and offset by a 2% fall in operating revenue in the quarter. The segment’s biopharmaceuticals portfolio reported revenue of $363 million in the second quarter, a 34% rise in operating revenue driven by an increase in US and European sales following the increased demand of the drugs Omnitrope and Zarxio in US markets and Erelzi and Rixathon in European markets.